SARS-CoV-2 co-infection

Guideline | Guideline Working Group Members | Grade recommendation strength and evidence quality definitions | Diagnosis | Risk factors for severe illness | SARS-CoV-2 co-infection | Initial illness severity assessment | Investigations | Monitoring | Respiratory support | Evidence-based approach to the use of respiratory support | Medication | Chest physiotherapy | Hydration/ nutrition | Safety initiatives | Discharge-planning and community-based management | Criteria for safe discharge | Prevention of RSV bronchiolitis | Summary of key changes in the recommendations between the 2016 guideline and 2025 update | 2016 guideline | Endorsements | Manuscripts | Education Modules

SARS-CoV-2 co-infection

SARS-CoV-2 infection or co-infection does not appear to place infants at increased risk of severe outcome from bronchiolitis. Do not routinely use SARS-CoV-2 status to stratify increased risk for deterioration in infants with bronchiolitis. (Evidence quality: very low; recommendation strength: weak)